Chimeric Adrenomedullin Analogs for CNS Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic candidates for CLR/RAMP receptor signaling, such as peptide antagonists and small molecule antagonists, face challenges including short half-lives, low potencies, liver toxicity, and limited access to the central nervous system, making them ineffective for treating conditions like migraines and cancer.
Innovation Solution
Development of chimeric adrenomedullin and intermedin analogs with N-terminal mini-PEG and acylation moieties that exhibit superagonistic or superantagonistic activity on CLR/RAMP receptors, enhancing receptor-activation potency and stability, and facilitating better access to the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide antagonists and small molecule antagonists are used for CLR/RAMP receptor signaling, then receptor blocking activity is achieved, but half-life is short and potency is low
Solution Approach 1:
The patent modifies the chemical structure of peptide antagonists by introducing N-terminal acylation and mini-PEG moieties, changing physical-chemical parameters to enhance pharmacokinetic properties. This resolves the contradiction by extending half-life while maintaining receptor blocking activity through structural optimization rather than fundamental mechanism changes.
Solution Approach 2:
The invention creates composite peptide molecules combining multiple functional elements: the core peptide sequence for receptor binding, N-terminal acylation for stability, and mini-PEG moieties for pharmacokinetic enhancement. This composite approach simultaneously achieves long half-life and high potency by integrating multiple beneficial properties into a single molecule.
2Reliability
If conventional antagonists are used for CLR/RAMP receptors, then receptor blocking is achieved, but liver toxicity occurs
Solution Approach 1:
The patent applies local modifications at specific positions of the peptide molecule - N-terminal acylation and mini-PEG attachment at the N-terminus - to improve pharmacokinetic properties without compromising the C-terminal region responsible for receptor binding. This localized optimization reduces liver toxicity while maintaining blocking activity.
Solution Approach 2:
The invention creates analogs and mimics of natural peptide hormones by copying their basic structure and function while introducing protective modifications. These copied molecules retain the essential receptor blocking activity but with improved safety profiles, reducing liver toxicity through structural variation.
3Reliability
If conventional antagonists are used for CLR/RAMP receptors, then peripheral receptor blocking is achieved, but access to central nervous system is limited
Solution Approach 1:
The patent designs multi-functional antagonists that can act at both peripheral and central CLR/RAMP receptors. By incorporating lipophilic modifications and mini-PEG moieties, the same molecule achieves blood-brain barrier penetration while maintaining peripheral blocking activity, providing universal applicability across different tissue compartments.
Solution Approach 2:
The invention transitions the pharmacological action from purely peripheral to a dual peripheral-central dimension. The structural modifications enable the antagonist to cross the blood-brain barrier, adding a central nervous system dimension to its activity while preserving peripheral function, thus expanding its therapeutic scope.
4Adaptability or versatility
If wild-type adrenomedullin and intermedin ligands are used, then natural receptor activation is achieved, but receptor-activation potency is insufficient
Solution Approach 1:
Instead of using the natural ligand to activate receptors, the patent inverts the approach by creating superagonists that stabilize a more uniform conformation than the endogenous agonist. This inverted strategy - using modified analogs rather than wild-type ligands - achieves supraphysiological efficacy by forcing the receptor into a fully active state.
Solution Approach 2:
The patent modifies the ligand structure by introducing N-terminal acylation and mini-PEG moieties, changing the physical-chemical parameters to enhance binding affinity and conformational stability. These parameter changes transform the natural ligand into a superagonist with superior potency while maintaining the ability to activate CLR/RAMP receptors.
Data Source
AI summary
Analogs for CLR/RAMP receptor ligands are provided that have agonist, superagonist, antagonist or superantagonist activity. The analogs can be selective for one or more CLR/RAMP receptors, or can be pan-specific.